Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Published In:
- Lancet (London, England), 402(10402), 613-626 (2023)
- Authors:
- Garvey, W Timothy(4), Frias, Juan P(5), Jastreboff, Ania M(5), le Roux, Carel W, Sattar, Naveed, Aizenberg, Diego, Mao, Huzhang, Zhang, Shuyu, Ahmad, Nadia N, Bunck, Mathijs C, Benabbad, Imane, Zhang, Xiaotian M
- Database ID:
- RPEP-06898
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06898APA
Garvey, W Timothy; Frias, Juan P; Jastreboff, Ania M; le Roux, Carel W; Sattar, Naveed; Aizenberg, Diego; Mao, Huzhang; Zhang, Shuyu; Ahmad, Nadia N; Bunck, Mathijs C; Benabbad, Imane; Zhang, Xiaotian M. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.. Lancet (London, England), 402(10402), 613-626. https://doi.org/10.1016/S0140-6736(23)01200-X
MLA
Garvey, W Timothy, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.." Lancet (London, 2023. https://doi.org/10.1016/S0140-6736(23)01200-X
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide once weekly for the treatment of obesity in peop..." RPEP-06898. Retrieved from https://rethinkpeptides.com/research/garvey-2023-tirzepatide-once-weekly-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.